MedTrace Logo

Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

NCT07034859 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-06-24

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Cabergoline (Dostinex), a dopamine agonist which has been widely used to treat hyperprolactinemia, prolactinoma for many years, works to treat nonfunctioning pituitary adenoma (NFPA) in adults. The main questions it aims to answer are:

Does cabergoline reduce the size of NFPA effectively when used as primary therapy?

Participants will:

Be 1:1 randomized into two groups. Either to take cabergoline or none for 48 weeks, Visit the clinic every 12 weeks for checkups and tests, Undergo scheduled imaging studies, Magnetic Resonance Imaging (MRI) to measure the change of tumor size.

Conditions

  • Pituitary Adenoma
  • MRI
  • RCT

Interventions

DRUG

Cabergoline 0.5 MG

Cabergoline (Dostinex ®) 0.5 mg/tablet. Cabergoline will be given orally 1mg/week (Day1-14), 2mg/week (Day15-end of the study).

Sponsors & Collaborators

  • National Taiwan University Hospital Beihu Branch

    collaborator OTHER

  • National Taiwan University

    collaborator OTHER

  • National Taiwan University Hospital Hsin-Chu Branch

    collaborator OTHER

  • National Taiwan University Hospital, Yun-Lin Branch

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2028-10-30
Completion
2028-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07034859 on ClinicalTrials.gov